Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Lung cancer is a leading cause of cancer mortality globally.
• Targeting the epidermal growth factor receptor (EGFR) and glutamine metabolism are potential strategies for lung cancer prevention and treatment.
• Modulating the tumor microenvironment to enhance anti-cancer immunity is a key area of research.

Purpose of the Study:

• To investigate the efficacy of JHU083, an orally active glutamine antagonist prodrug, in combination with an EGFR peptide vaccine (EVax) against EGFR-driven lung tumorigenesis.
• To elucidate the immunological mechanisms underlying the combined therapeutic effect.

Main Methods:

• Utilized EGFR-driven mouse lung cancer models.
• Administered JHU083 and EVax as single agents and in combination.
• Employed flow cytometry and single-cell RNA sequencing to analyze immune cell populations and phenotypes within the tumor microenvironment.

Main Results:

• Combination therapy with JHU083 and EVax significantly suppressed lung tumor development compared to single treatments.
• JHU083 increased CD8+ T cell and CD4+ Th1 cell infiltration and decreased immunosuppressive cells (MDSCs, Tregs, Th17 cells).
• EVax induced Th1 cell-mediated immune responses, and Th1 cells upregulated oxidative metabolism and adopted an activated, memory-like phenotype under glutamine inhibition.

Conclusions:

• JHU083 is effective against EGFR-driven lung tumorigenesis.
• The combination of JHU083 and EVax promotes an adaptive, T cell-mediated immune response that enhances anti-tumor efficacy.
• Targeting glutamine metabolism alongside EGFR vaccination represents a promising strategy for lung cancer treatment.